235 results
8-K
EX-10.3
DMKPQ
DMK Pharmaceuticals Corp
19 Oct 23
Entry into a Material Definitive Agreement
5:07pm
procedure shall be your sole responsibility.
(c) You may not exercise your option, unless the tax withholding obligations of the Company and/or any
8-K
DMKPQ
DMK Pharmaceuticals Corp
19 Oct 23
Entry into a Material Definitive Agreement
5:07pm
to public, private equity backed, and start-up businesses. From 2000 to 2011, Mr. Cohen served in various leadership roles of increasing responsibility
8-K
EX-10.4
DMKPQ
DMK Pharmaceuticals Corp
19 Oct 23
Entry into a Material Definitive Agreement
5:07pm
such exercise. Any adverse consequences to you arising in connection with such share withholding procedure shall be your sole responsibility.
(c) You may
DEFC14A
cf15yk
12 Oct 23
Proxy in contested solicitation
4:22pm
PREC14A
mtv14zp5h75uzx9l0yz5
2 Oct 23
Preliminary proxy with contested solicitation
4:49pm
8-K
EX-5.1
9k343 5bia
3 Aug 23
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
4:59pm
8-K
EX-10.1
n5evxex
3 Aug 23
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
4:59pm
8-K
EX-99.1
fm5dwzd
3 Aug 23
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
4:59pm
8-K
EX-1.1
n9y27vf
3 Aug 23
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
4:59pm
424B4
ys1vvpxn8o5ey cd
3 Aug 23
Prospectus supplement with pricing info
4:55pm
8-K
EX-10.2
9lxwcli e6pfkiivxf
24 Jul 23
Entry into a Material Definitive Agreement
4:20pm